CN103191140B - 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 - Google Patents
大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 Download PDFInfo
- Publication number
- CN103191140B CN103191140B CN201310087383.6A CN201310087383A CN103191140B CN 103191140 B CN103191140 B CN 103191140B CN 201310087383 A CN201310087383 A CN 201310087383A CN 103191140 B CN103191140 B CN 103191140B
- Authority
- CN
- China
- Prior art keywords
- emodin
- glucosule
- cell
- glucoside
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZXXFEBMBNPRRSI-UHFFFAOYSA-N 3'-Prenyl-4'-methoxy-isoflavone-7-O'-??-D-(2''-O-p-coumaroyl)glycopyranoside Natural products C=12C(=O)C3=C(O)C=C(O)C=C3C(=O)C2=CC(C)=CC=1OC1OC(CO)C(O)C(O)C1O ZXXFEBMBNPRRSI-UHFFFAOYSA-N 0.000 title abstract description 10
- HSWIRQIYASIOBE-UHFFFAOYSA-N Emodin-8-O-beta-D-glucosid Natural products C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O HSWIRQIYASIOBE-UHFFFAOYSA-N 0.000 title abstract description 10
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 9
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 2
- 201000007270 liver cancer Diseases 0.000 abstract description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 39
- 230000001629 suppression Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 6
- 201000010989 colorectal carcinoma Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- JAABVEXCGCXWRR-UHFFFAOYSA-N norcantharidin Chemical compound C1CC2C3C(=O)OC(=O)C3C1O2 JAABVEXCGCXWRR-UHFFFAOYSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001249696 Senna alexandrina Species 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 241000123835 Ampelopsis japonica Species 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 241001646826 Isodon rubescens Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 240000007001 Rumex acetosella Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 231100000238 embryotoxicity Toxicity 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其在制备肿瘤治疗和预防药物或食品中的新用途。在一定浓度范围内，大黄素-8-O-β-D-葡萄糖苷可以选择性地杀伤人肝癌细胞、结直肠癌细胞等多种癌细胞，而不影响人体正常细胞的活力和功能。因此可被用于制备抗肿瘤药物和预防肿瘤发生的药物或食品。
Description
发明领域
本发明涉及大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其在医药和食品领域的新用途。
背景技术
大黄素-8-O-β-D-葡萄糖苷主要分布于蓼科何首乌(Polygonum multiflorum Thunb.)、虎杖(Polygonum cuspidatum Sieb.et Zucc.)、掌叶大黄(Rheum palamatum L.)、豆科决明(Cassiaobtusifolia L.)、狭叶番泻(Cassia angustifolia Vahl)、唇形科碎米桠(Rabdosia rubescens Hara)、葡萄科白蔹(Ampelopsis japonica Makino)等多科属药用植物中(王文静，等.云南中医学院学报，2005，28(1)：10-12；陈志强，栾颖，中国药房，2009，20(9)：688-689；田国芳，等.中国中药杂志，2010，35(18)：2437-2439；唐力英，等.中国实验方剂学杂志，2009，15(7)：35-37；邬秋萍，等.中药材，2007，30(10)：1250-1252；吕芳，徐筱杰.中药材，2008，31(9)：1340-1343；赫军，等.沈阳药科大学学报，2009，26(3)：188-190)。过去报道其有一定促智作用，对脑中的真性乙酰胆碱酯酶具有良好的可逆性抑制作用，对β淀粉样蛋白造成的海马神经元损伤具有一定的保护作用，并能显著改善由东莨菪碱导致的小鼠学习记忆功能障碍，显著提高正常小鼠学习记忆获得能力。急性毒性实验表明口服大黄素-8-O-β-D-葡萄糖苷具有较高的安全性(陈万生等，专利号99119950226；中草药，2001，32(1)：39-41)。我们研究发现化合物大黄素-8-O-β-D-葡萄糖苷具有良好的抗肿瘤作用，特别是对人肝癌、结直肠癌等，在一定浓度范围内，对肿瘤细胞具杀伤作用而不影响人正常体细胞的活力和功能。
发明内容
本发明内容涉及化合物大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其在制备癌症治疗和预防药物或食品中的新用途。
本发明所指的抗肿瘤活性为抗肝癌、结直肠癌等多种肿瘤的活性。大黄素-8-O-β-D-葡萄糖苷对多种人体肿瘤细胞，包括肝癌和结直肠癌细胞，具有选择性的杀伤作用。该化合物可剂量依赖性地将人肝癌细胞阻滞在G2-M期，并诱导其发生凋亡，但是不影响人体正常细胞的活力和功能。因此，大黄素-8-O-β-D-葡萄糖苷具有高效抗肿瘤且低毒等特点。据此，大黄素-8-O-β-D-葡萄糖苷可被用于制备抗肿瘤药物和预防肿瘤发生的药物或食品。
附图说明
图1是大黄素-8-O-β-D-葡萄糖苷作用于人肝癌HepG2细胞及人正常肝实质L02细胞0～72h的抑制率图。
图2是不同浓度大黄素-8-O-β-D-葡萄糖苷诱导HepG2细胞凋亡图。
图3是大黄素-8-O-β-D-葡萄糖苷对人肝癌HepG2细胞周期的影响图。
图4是大黄素-8-O-β-D-葡萄糖苷作用人结直肠癌HT-29细胞72h的抑制率图。
图5是大黄素-8-O-β-D-葡萄糖苷作用大鼠心肌H9c2细胞48h的抑制率图。
具体实施方式
下面通过具体实施例来对本发明作进一步的说明，但这些实施例只是为了说明，而不是对本发明的限制。
实施例
1.大黄素-8-O-β-D-葡萄糖苷对人肝癌HepG2细胞及人正常肝实质L02细胞活力的影响
采用MTT比色法比较大黄素-8-O-β-D-葡萄糖苷对人肝癌HepG2细胞和人正常肝实质L02细胞的细胞毒性。两种细胞分别以1600个/孔的密度接种于96孔板，孵育12～24h，设50μg/mL、100μg/mL、200μg/mL、300μg/mL四个给药组，并设空白溶剂对照组(0.1％DMSO)和去甲斑蝥素(NCTD，10μg/mL)阳性对照组，每组8个复孔。分别测0h、24h、48h、72h四个时相各孔细胞的OD值，并做抑制率直方图。抑制率＝(1-加药组OD值/对照组OD值)×100％，结果见图1。
图1不同浓度大黄素-8-O-β-D-葡萄糖苷作用于人肝癌HepG2细胞及人正常肝实质L02细胞0～72h的抑制率图：
A.不同浓度大黄素-8-O-β-D-葡萄糖苷对人肝癌HepG2细胞的抑制率图
B.不同浓度大黄素-8-O-βD-葡萄糖苷对人正常肝实质L02细胞的抑制率图
结论：由图1比较可知，在50～200μg/mL范围内，大黄素-8-O-β-D-葡萄糖苷对肝癌HepG2细胞的生长抑制作用呈现明显的时间-剂量依赖性，而对人正常肝实质L02细胞活力无显著影响。
2.大黄素-8-O-β-D-葡萄糖苷诱导人肝癌HepG2细胞凋亡
本实验采用Annexin V-FITC和PI双染细胞，流式细胞术检测细胞凋亡率。与上述MTT实验相同密度的肝癌HepG2细胞接种于直径10cm平皿中，孵育12～24h，除溶剂空白对照组外分别加50μg/mL、100μg/mL、200μg/mL的大黄素-8-O-β-D-葡萄糖苷作用细胞72h，收集全细胞，离心弃上清，磷酸盐缓冲液洗2遍，加Binding buffer重悬细胞，加10μLAnnexin V-FITC染液避光反应15min，加5μLPI染液混匀后上机检测，结果见图2。
图2不同浓度大黄素-8-O-β-D-葡萄糖苷诱导HepG2细胞凋亡
A大黄素-8-O-β-D-葡萄糖苷50μg/mL组 B大黄素-8-O-β-D葡萄糖苷100μg/mL组C大黄素-8-O-β-D葡萄糖苷200μg/mL组 D空白对照组
各组凋亡率整理见表1：
表1大黄素-8-O-β-D-葡萄糖苷作用人肝癌HepG2细胞72h凋亡率
结论：由图2和表1数据可知，50、100、200μg/mL3个浓度的大黄素-8-O-β-D-葡萄糖苷诱导肝癌HepG2细胞的凋亡率都比空白对照组明显增高，凋亡率随大黄素-8-O-β-D-葡萄糖苷浓度的增加而增加，有明显的剂量依赖性，其中200μg/mL组细胞凋亡率达到33.4％。
3.大黄素-8-O-β-D-葡萄糖苷对人肝癌HepG2细胞周期的影响
本实验采用细胞PI染色、流式细胞仪检测的方法测定大黄素-8-O-β-D-葡萄糖苷对肝癌HepG2细胞周期的影响。与MTT实验相同密度的肝癌HepG2细胞接种于直径10cm的平皿中，孵育12～24h，加大黄素-8-O-β-D-葡萄糖苷至终浓度为200μg/mL，作用72h，另设溶剂空白对照组。收集全细胞，磷酸盐缓冲液洗2遍，70％冰乙醇4℃固定保存过夜。1000r/min离心5min弃去固定液，用磷酸盐缓冲液洗涤2次。用500μL PBS重悬细胞，加入RNaseA使终浓度为20μg/mL，37℃水浴，45min。加入PI染液使终浓度为50μg/mL，4℃避光染色60min。流式细胞仪检测，结果见图3。
图3大黄素-8-O-β-D-葡萄糖苷对人肝癌HepG2细胞周期的影响
A空白对照
B200μg/mL大黄素-8-O-β-D葡萄糖苷作用72h
结论：由图3，空白对照组G2-M期细胞的比例为11.70％；大黄素-8-O-β-D葡萄糖苷组G2-M期的细胞比例为19.19％，说明大黄素-8-O-β-D葡萄糖苷可以一定程度诱导人肝癌HepG2细胞发生G2-M期阻滞，影响其正常生长。
4.大黄素-8-O-β-D-葡萄糖苷对人结直肠癌HT-29细胞活力的影响
采用MTT比色法检测大黄素-8-O-β-D-葡萄糖苷对人结直肠癌HT-29细胞的细胞毒性。以1600个/孔的密度接种于96孔板，孵育12～24h，药物设50μg/mL、100μg/mL、150μg/mL、200μg/mL、300μg/mL四组，设空白对照组和去甲斑蝥素(NCTD，10μg/mL)阳性对照组，每组8个复孔。测定72h各孔细胞的OD值做大黄素-8-O-β-D-葡萄糖苷抑制率直方图。抑制率＝(1-加药组OD值/对照组OD值)×100％，结果见图4。
图4大黄素-8-O-β-D-葡萄糖苷作用人结直肠癌HT-29细胞72h的抑制率图
结论：由图4可知，在50～300μg/mL剂量范围内，大黄素-8-O-β-D-葡萄糖苷对人结直肠癌HT-29细胞的杀伤作用有明显的剂量依赖性，对癌细胞的生长抑制作用随浓度的升高而增强。
5.大黄素-8-O-β-D-葡萄糖苷对大鼠心肌细胞活力的影响
采用MTT比色法检测大黄素-8-O-β-D-葡萄糖苷对大鼠心肌H9c2细胞的细胞毒性作用。以1600个/孔的密度接种于96孔板，孵育12～24h，大黄素-8-O-β-D-葡萄糖苷设50μg/mL、100μg/mL、150μg/mL、200μg/mL、250μg/mL组，设空白对照组和去甲斑蝥素(NCTD，10μg/mL)阳性对照组，每组8个复孔。测定48h各孔细胞的OD值做抑制率直方图。抑制率＝(1-加药组OD值/对照组OD值)×100％，见图5。
图5大黄素-8-O-β-D-葡萄糖苷作用大鼠心肌H9c2细胞48h的抑制率图
结论：由图5可知，大黄素-8-O-β-D葡萄糖苷在50～250μg/mL浓度范围内对大鼠心肌H9c2细胞的生长毒性作用较小，不影响细胞的正常生长。
Claims (2)
1.大黄素-8-O-β-D-葡萄糖苷在制备预防或治疗肝癌或结直肠癌药物中的用途。
2.根据权利要求1所述用途，其特征在于所述肿瘤为肝癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310087383.6A CN103191140B (zh) | 2013-03-19 | 2013-03-19 | 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310087383.6A CN103191140B (zh) | 2013-03-19 | 2013-03-19 | 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103191140A CN103191140A (zh) | 2013-07-10 |
| CN103191140B true CN103191140B (zh) | 2015-04-01 |
Family
ID=48714076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310087383.6A Active CN103191140B (zh) | 2013-03-19 | 2013-03-19 | 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191140B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845420B (zh) * | 2014-02-26 | 2016-03-16 | 东南大学 | 一种塔黄提取物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101362702A (zh) * | 2008-09-12 | 2009-02-11 | 南昌大学 | 大黄素衍生物及其在制备抗癌药物中的应用 |
| CN102391095A (zh) * | 2011-08-11 | 2012-03-28 | 四川大学华西医院 | 大黄素衍生物及其用途 |
-
2013
- 2013-03-19 CN CN201310087383.6A patent/CN103191140B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101362702A (zh) * | 2008-09-12 | 2009-02-11 | 南昌大学 | 大黄素衍生物及其在制备抗癌药物中的应用 |
| CN102391095A (zh) * | 2011-08-11 | 2012-03-28 | 四川大学华西医院 | 大黄素衍生物及其用途 |
Non-Patent Citations (1)
| Title |
|---|
| Nam-Jae LEE,等.Antimutagenicity and Cytotoxicity of the Constituents from the Aerial Parts of Rumex acetosa.《Biol. Pharm. Bull.》.2005,第28卷(第11期),2158-2161. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103191140A (zh) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| An et al. | Apoptotic pathway as the therapeutic target for anticancer traditional Chinese medicines | |
| Tavakoli et al. | Evaluation of effectiveness of herbal medication in cancer care: a review study | |
| Zhang et al. | Natural product interventions for chemotherapy and radiotherapy-induced side effects | |
| Yue et al. | Natural products as adjunctive treatment for pancreatic cancer: recent trends and advancements | |
| Kapadia et al. | Synergistic cytotoxicity of red beetroot (Beta vulgaris L.) extract with doxorubicin in human pancreatic, breast and prostate cancer cell lines | |
| Wagner et al. | Chromatographic fingerprint analysis of herbal medicines | |
| Peng et al. | Botany, phytochemistry, pharmacology, and potential application of Polygonum cuspidatum Sieb. et Zucc.: a review | |
| Hosseini et al. | Reversal of doxorubicin-induced cardiotoxicity by using phytotherapy: a review | |
| Monteiro et al. | Medicinal plants and other living organisms with antitumor potential against lung cancer | |
| Chen et al. | FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review | |
| Liu et al. | Cardiotoxicity of doxorubicin-based cancer treatment: what is the protective cognition that phytochemicals provide us? | |
| Saedi et al. | The effects of herbs and fruits on leukaemia | |
| Zheng et al. | Research advances in lotus leaf as Chinese dietary herbal medicine | |
| Gaidhani et al. | Evaluation of some plant extracts for standardization and anticancer activity | |
| Wu et al. | Regulatory role of chinese herbal medicine in regulated neuronal death | |
| Dai et al. | Chinese herbal medicine for hyperlipidaemia: a review based on data mining from 1990 to 2016 | |
| Behravan et al. | Review of plants and their constituents in the therapy of cerebral ischemia | |
| US9789153B2 (en) | Composition for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs | |
| Li et al. | In vitro antioxidant, immunomodulatory and anticancer activities of two fractions of aqueous extract from Helicteres angustifolia L. root | |
| Yu et al. | Effects of Hydrocotyle sibthorpioides extract on transplanted tumors and immune function in mice | |
| Wang et al. | Overcoming chemotherapy resistance with herbal medicines: past, present and future perspectives | |
| Song et al. | Traditional Chinese medicine for treatment of sepsis and related multi-organ injury | |
| CN103191140B (zh) | 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 | |
| CN108434399A (zh) | 一种防治肿瘤的中药组合物及制备方法 | |
| Begum et al. | Effects of ethanolic leaf extract of Azim tetracantha Lam. on Ehrlich ascites carcinoma tumour bearing mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Sun Zhenxiao Inventor after: Li Dengke Inventor after: Li Baosai Inventor after: Wang Rufeng Inventor before: Sun Zhenxiao Inventor before: Li Baosai Inventor before: Wang Rufeng |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SUN ZHENXIAO LI BAOSAI WANG RUFENG TO: SUN ZHENXIAO LI DENGKE LI BAOSAI WANG RUFENG |
|
| DD01 | Delivery of document by public notice |
Addressee: Sun Zhenxiao Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 102488 Liangxiang University Town, Fangshan District, Beijing Patentee after: Sun Zhenxiao Address before: 100102 Department of Biopharmaceutics, School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6 South Central Road, Wangjing, Beijing, Chaoyang District Patentee before: Sun Zhenxiao |